| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Steinhart Richard I | Chief Financial Officer | C/O BIOXCEL THERAPEUTICS, INC., 555 LONG WHARF DRIVE, 12TH FLOOR, NEW HAVEN | /s/ Richard Steinhart | 22 Jul 2025 | 0001293789 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | BTAI | Common Stock | Award | +4,375 | +304% | 5,816 | 22 Jul 2025 | Direct | F1 | ||
| transaction | BTAI | Common Stock | Options Exercise | +625 | +11% | 6,441 | 22 Jul 2025 | Direct | F2 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | BTAI | Restricted Stock Units | Options Exercise | $0 | -625 | -100% | $0.000000 | 0 | 22 Jul 2025 | Common Stock | 625 | Direct | F2, F3 |
| Id | Content |
|---|---|
| F1 | The Issuer previously granted the Reporting Person an award of restricted stock units that would vest based on the Issuer's satisfaction of certain performance objectives and subject to the Reporting Person's continued service with the Issuer through July 22, 2025 (the "PSUs"). On July 22, 2025, the Compensation Committee of the Issuer's Board of Directors determined that performance conditions with respect to 4,375 PSUs had been satisfied and 4,375 shares of common stock became issuable to the Reporting Person on July 22, 2025. |
| F2 | Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. |
| F3 | On July 22, 2024, the Reporting Person was granted 625 RSUs, which vested as to 100% of the total number of RSUs on the first anniversary of the grant date. |